GO:1990549 mitochondrial NAD transmembrane transport: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1990549 (mitochondrial NAD transmembrane transport) is the biological process by which NAD is moved across a mitochondrial membrane, into or out of the mitochondrion.
• The process is essential because mitochondria cannot synthesize NAD de novo and must import it to sustain oxidative phosphorylation and redox homeostasis.
• SLC25A51 is the principal mammalian mitochondrial NAD+ carrier, and its loss impairs mitochondrial NAD+ pools and respiration.
• In yeast, the orthologous transporter Ndt1p uses conserved charged residues in its C- and M-gates to recognize and translocate NAD+.
• Mitochondrial NAD transport is a therapeutic node in acute kidney injury-to-chronic kidney disease progression and in acute myeloid leukemia.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are the standard tools for dissecting transporter function and disease causality.
Description
Mitochondrial NAD transmembrane transport (GO:1990549) is defined as the process in which NAD is transported across a mitochondrial membrane, into or out of the mitochondrion. This process is fundamental to mitochondrial biology because the organelle depends on imported NAD to maintain the redox balance required for oxidative phosphorylation and for the activity of NAD-dependent enzymes such as sirtuins and PARPs. The identification of SLC25A51 as a mammalian mitochondrial NAD+ transporter has made this GO term a focal point for cancer metabolism, ischemia-reperfusion injury, and mitochondrial disease research. In parallel, the yeast transporter Ndt1p has provided a genetically tractable model for dissecting the molecular determinants of NAD+ recognition and transport. The term matters to researchers because mitochondrial NAD levels are not simply a passive reflection of cytosolic pools; they are actively regulated by dedicated transport machinery. Loss of mitochondrial NAD import compromises respiration and renders cells vulnerable to metabolic stress, a phenotype relevant to acute kidney injury and leukemia. Conversely, enhancing mitochondrial NAD availability through nanoparticle-mediated delivery has been shown to promote mitochondrial repair and reduce inflammation in AKI-to-CKD progression. Because GO:1990549 is a transport process rather than a single gene product, its study spans membrane bioenergetics, transporter biochemistry, and disease modeling. This article synthesizes the authoritative GO definition with verified literature to provide a publication-ready overview of the mechanism, key genes, disease links, and experimental strategies for investigating mitochondrial NAD transmembrane transport.
mitochondrial NAD transmembrane transport At A Glance
| GO ID | GO:1990549 |
|---|---|
| GO term | mitochondrial NAD transmembrane transport |
| Ontology | biological_process |
| Synonym | none |
| Major function | Transport of NAD across a mitochondrial membrane, into or out of the mitochondrion |
| Molecular mediators | SLC25A51 in mammals; Ndt1p in yeast |
| Directionality | Into or out of the mitochondrion |
| Disease relevance | Acute kidney injury-to-CKD progression; acute myeloid leukemia |
| Research methods | CRISPR knockout, point mutation, knock-in, overexpression, transporter biochemistry |
What Is GO:1990549?
In our own words, GO:1990549 describes the directed movement of NAD across a mitochondrial membrane, either from the cytosol into the mitochondrial matrix or in the reverse direction. It is a biological_process term that captures the transport step itself, not the downstream redox reactions that consume or produce NAD. The process is required because mitochondria lack a complete NAD salvage pathway and therefore depend on transporter proteins to supply the organelle with NAD. The yeast Ndt1p and its mammalian counterpart SLC25A51 are the best-characterized molecular mediators of this activity.
Why Is mitochondrial NAD transmembrane transport Important in Cell Biology?
Mitochondrial NAD transmembrane transport is important because it sets the size of the mitochondrial NAD pool, which in turn controls oxidative phosphorylation, sirtuin activity, and cellular stress responses. When this transport process is impaired, mitochondria cannot sustain respiration, and cells become susceptible to metabolic and inflammatory injury. The process is therefore a convergence point for cancer metabolism, kidney disease, and mitochondrial dysfunction research.
• Maintains the mitochondrial NAD pool required for oxidative phosphorylation and ATP production.
• Supports NAD-dependent enzymes including sirtuins and PARPs inside mitochondria.
• Loss of SLC25A51-mediated transport impairs respiration and mitochondrial function.
• Mitochondrial NAD transport is implicated in acute kidney injury-to-CKD progression.
• SLC25A51 is a candidate therapeutic target in acute myeloid leukemia.
• Nanoparticle-mediated NAD delivery can promote mitochondrial repair and reduce inflammation.
• Yeast Ndt1p provides a genetically tractable model for transporter structure-function studies.
• The process links cytosolic NAD metabolism to mitochondrial redox homeostasis.
• Dysregulation contributes to metabolic stress and cell death in disease models.
• CRISPR models enable causal testing of transporter genes in disease phenotypes.
What Happens During mitochondrial NAD transmembrane transport?
Substrate recognition at the mitochondrial membrane
In simple terms: The transporter first has to recognize NAD as the correct cargo before it can move it.
Mitochondrial NAD transmembrane transport begins with recognition of NAD by a dedicated carrier protein embedded in the mitochondrial membrane. In yeast, the mitochondrial NAD+ transporter Ndt1p uses charged residues in its C- and M-gates to discriminate NAD+ from related metabolites. This substrate recognition step is the first committed event in the transport cycle and determines the specificity of the process.
Conformational cycling of the carrier
In simple terms: The transporter changes shape to shuttle NAD across the membrane.
After substrate binding, the carrier undergoes conformational cycling that moves NAD across the mitochondrial membrane. Functional analysis of Ndt1p charged residues in the C- and M-gates has shown that these gates control the alternating access mechanism required for transport. Disruption of these residues alters transport activity, demonstrating that the conformational cycle is essential for GO:1990549.
Delivery of NAD into the mitochondrial compartment
In simple terms: NAD is released on the other side of the membrane so the mitochondrion can use it.
The transport cycle terminates with release of NAD into the mitochondrial compartment, where it becomes available for redox reactions and signaling. Because mitochondria cannot synthesize NAD de novo, this delivery step is the principal route for maintaining the organellar NAD pool. Loss of the mammalian transporter SLC25A51 reduces mitochondrial NAD+ and impairs respiration, confirming the functional importance of delivery.
Coupling to mitochondrial redox and energy metabolism
In simple terms: Once inside, NAD feeds the reactions that make energy.
Imported NAD supports the redox reactions of oxidative phosphorylation and the activity of NAD-consuming enzymes. The transmembrane difference in NAD+ redox potential across the mitochondrial membrane is a measurable parameter of mitochondrial energy state. In this way, GO:1990549 is mechanistically coupled to mitochondrial membrane potential and energy metabolism.
Pharmacological and nanoparticle modulation of transport
In simple terms: Scientists can boost or bypass transport to repair mitochondria.
Experimental strategies have been developed to modulate mitochondrial NAD availability therapeutically. Ultrasmall polyphenol-NAD+ nanoparticles have been used for renal delivery to promote mitochondrial repair and reduce inflammation in AKI-to-CKD progression. Such approaches complement genetic manipulation of transporters and highlight the translational relevance of GO:1990549.
Key Genes Involved in GO:1990549 mitochondrial NAD transmembrane transport
The following genes and proteins have been experimentally linked to mitochondrial NAD transmembrane transport or to the mitochondrial NAD pool it supplies.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC25A51 | Principal mammalian mitochondrial NAD+ transporter | Therapeutic target in acute myeloid leukemia; required for mitochondrial NAD+ and respiration |
| NDT1 | Yeast mitochondrial NAD+ transporter | Model for structure-function analysis of C- and M-gates |
| NDT2 | Yeast mitochondrial NAD+ transport family member | Comparative transporter studies |
| SLC25A52 | Mitochondrial carrier family member | Candidate NAD transport modifier |
| SLC25A53 | Mitochondrial carrier family member | Candidate NAD transport modifier |
| NAMPT | NAD salvage enzyme upstream of transport | Determines cytosolic NAD supply for import |
| NMNAT | NAD synthesis enzyme | Supplies NAD for mitochondrial import |
| SIRT3 | Mitochondrial NAD-dependent deacetylase | Readout of mitochondrial NAD availability |
| PARP1 | NAD-consuming enzyme | Competes for mitochondrial NAD pools |
| Complex I | NADH:ubiquinone oxidoreductase | Consumes NADH derived from imported NAD |
| Complex III | Cytochrome bc1 complex | Linked to transmembrane NAD+ redox potential |
| Transhydrogenase | NADPH to NAD+ transhydrogenase | Interconverts NADP and NAD pools in mitochondria |
| Glutamate-aspartate translocase | Mitochondrial metabolite exchanger | Equilibrates with NAD+ redox potential |
| NOX family | NADPH oxidases | Cytosolic NADPH-consuming enzymes relevant to cardiac failure |
| Coenzyme Q | Electron carrier | Non-mitochondrial coenzyme Q biology intersects with NAD redox |
How Is mitochondrial NAD transmembrane transport Regulated?
Mitochondrial NAD transmembrane transport is regulated at the level of transporter expression and by the availability of cytosolic NAD. In mammalian cells, SLC25A51 abundance and activity determine mitochondrial NAD+ levels, and its loss reduces respiration. In yeast, charged residues in the C- and M-gates of Ndt1p regulate the transport cycle, providing a structural basis for activity control. Pharmacological delivery of NAD+ via nanoparticles can bypass transporter limitations and enhance mitochondrial repair.
mitochondrial NAD transmembrane transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC25A51 | Acute myeloid leukemia | CRISPR knockout in AML cell lines |
| SLC25A51 | Mitochondrial NAD+ depletion and impaired respiration | Overexpression and rescue models |
| NDT1 | Yeast mitochondrial NAD+ transport | Point-mutation of C- and M-gate residues |
| NAMPT | NAD salvage and renal injury | Nanoparticle delivery and knockout models |
| Transhydrogenase | Parasite mitochondrial NADPH/NAD balance | Enzyme purification and activity assays |
Mitochondrial NAD transport in acute kidney injury and CKD progression
Mitochondrial dysfunction and NAD depletion contribute to the progression from acute kidney injury to chronic kidney disease. Ultrasmall polyphenol-NAD+ nanoparticles delivered to the kidney promote mitochondrial repair and reduce inflammation, slowing AKI-to-CKD progression. These findings link mitochondrial NAD availability, and by extension GO:1990549, to renal disease outcomes.
SLC25A51 and acute myeloid leukemia
SLC25A51-mediated mitochondrial NAD+ transport is a mechanism of interest in acute myeloid leukemia, where leukemic cells depend on mitochondrial metabolism. Targeting this transport process has been proposed as a therapeutic strategy, and translational perspectives have been reviewed. This makes GO:1990549 a candidate pathway for leukemia therapy development.
Cardiac failure and NADPH oxidase biology
NADPH oxidases consume NADPH and contribute to cardiac failure, a setting in which mitochondrial redox balance is disturbed. Although NOX enzymes are not mitochondrial NAD transporters, their activity influences the cytosolic NADPH/NAD pool that feeds mitochondrial transport. This contextualizes GO:1990549 within cardiovascular redox pathology.
Parasite and non-mammalian mitochondrial NAD metabolism
Mitochondrial NADPH to NAD transhydrogenase activity has been characterized in the cestode Hymenolepis diminuta, showing that mitochondrial NAD metabolism is conserved across diverse organisms. These studies provide comparative insight into the enzymes that interconvert NAD and NADP pools. They also highlight non-mitochondrial coenzyme Q biology as a related redox theme.
From mitochondrial NAD transmembrane transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is SLC25A51 required for mitochondrial NAD+ and respiration? | CRISPR knockout in mammalian cell lines |
| Which residues control NAD+ recognition in Ndt1p? | Point-mutation of C- and M-gate residues in yeast |
| Can restored transport rescue mitochondrial function? | Knock-in or overexpression rescue models |
| Does transporter loss alter disease phenotypes? | Knockout in leukemia or kidney injury models |
| Can nanoparticle NAD delivery bypass transport defects? | Pharmacological nanoparticle delivery models |
| How does transport affect redox potential? | Tagged knock-in and live-cell redox imaging |
How to Study the mitochondrial NAD transmembrane transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function phenotype | Test requirement for SLC25A51 in respiration |
| Site-directed mutagenesis | Residue-level transport activity | Map Ndt1p C- and M-gates |
| Mitochondrial NAD+ assay | Organellar NAD pool size | Quantify transport capacity |
| Redox potential measurement | Transmembrane NAD+ redox difference | Assess mitochondrial energy state |
| Nanoparticle delivery | Mitochondrial repair and inflammation | Therapeutic NAD supplementation |
| Enzyme purification | Transhydrogenase activity | Characterize NAD/NADP interconversion |
| Live-cell imaging | Membrane potential and NAD dynamics | Monitor transport in real time |
Genetic knockout and rescue
CRISPR knockout of SLC25A51 or NDT1 followed by rescue with wild-type or mutant transporters is the standard approach to test causality in mitochondrial NAD transport. These experiments measure mitochondrial NAD+ levels, respiration, and downstream phenotypes.
Transporter biochemistry and mutagenesis
Purification and activity assays of mitochondrial NAD transporters, combined with site-directed mutagenesis of gate residues, define the molecular determinants of transport. Yeast Ndt1p is particularly useful for this purpose.
Redox and membrane potential measurements
Mitochondrial membrane potential and the transmembrane difference in NAD+ redox potential can be measured to assess the functional consequences of transport. These readouts connect GO:1990549 to mitochondrial energy state.
Nanoparticle delivery and imaging
Ultrasmall polyphenol-NAD+ nanoparticles enable renal delivery and mitochondrial repair, and can be combined with imaging to track NAD availability. Such methods test whether bypassing transporter limitations is therapeutic.
How CRISPR Can Be Used to Study GO:1990549 mitochondrial NAD transmembrane transport
Knockout
CRISPR knockout of SLC25A51 or NDT1 is used to eliminate mitochondrial NAD transport and measure the resulting loss of mitochondrial NAD+, respiration, and viability. These models establish whether the transporter is required for the process and for downstream phenotypes.
Point Mutation
Point mutation of charged residues in the C- and M-gates of Ndt1p allows precise testing of their role in NAD+ recognition and translocation. Such mutants separate substrate binding from conformational cycling.
Knock-in
Knock-in of tagged or mutant transporters enables tracking of protein localization and function in mitochondria. This approach can also restore transport in knockout backgrounds to test rescue.
Overexpression
Overexpression of SLC25A51 or Ndt1p increases mitochondrial NAD transport capacity and can enhance respiration or protect against metabolic stress. Overexpression models are useful for gain-of-function studies and for testing therapeutic hypotheses.
How EDITGENE Supports mitochondrial NAD transmembrane transport Research
Researchers studying mitochondrial NAD transmembrane transport-related genes often need to determine whether a candidate gene is causally involved in mitochondrial NAD supply, respiration, or disease phenotypes. EDITGENE provides the CRISPR cell models and screening services required to move from correlation to causation.
Contact EDITGENE today to design your custom CRISPR model for mitochondrial NAD transmembrane transport research.
Frequently Asked Questions About mitochondrial NAD transmembrane transport
What is mitochondrial NAD transmembrane transport?
It is the biological process, GO:1990549, in which NAD is transported across a mitochondrial membrane, into or out of the mitochondrion.
What genes are involved in mitochondrial NAD transmembrane transport?
SLC25A51 is the principal mammalian transporter, and NDT1 is the yeast ortholog used for mechanistic studies.
Why do mitochondria need to import NAD?
Mitochondria cannot synthesize NAD de novo and depend on import to maintain the NAD pool needed for respiration and NAD-dependent enzymes.
What happens when mitochondrial NAD transport is lost?
Loss of SLC25A51 reduces mitochondrial NAD+ and impairs respiration, linking the process to metabolic stress.
Is mitochondrial NAD transport involved in cancer?
SLC25A51-mediated transport is a therapeutic target of interest in acute myeloid leukemia.
Can mitochondrial NAD transport be targeted in kidney disease?
Nanoparticle-mediated NAD delivery promotes mitochondrial repair and reduces inflammation in AKI-to-CKD progression.
Which model organism is used to study NAD transporters?
Yeast Ndt1p is a tractable model for structure-function analysis of mitochondrial NAD+ transport.
How is mitochondrial NAD transport measured?
Mitochondrial NAD+ levels, respiration, and transmembrane NAD+ redox potential are common readouts.
What CRISPR models are used for this process?
Knockout, point-mutation, knock-in, and overexpression models are used to test transporter function and disease causality.
What diseases are linked to mitochondrial NAD transport?
Acute kidney injury-to-CKD progression and acute myeloid leukemia are the best-supported disease links.
Conclusion
GO:1990549 mitochondrial NAD transmembrane transport is a defined biological process that supplies mitochondria with NAD and thereby supports respiration and redox homeostasis. SLC25A51 in mammals and Ndt1p in yeast are the key molecular mediators, and their dysfunction is linked to kidney disease and leukemia. CRISPR-based knockout, point-mutation, knock-in, and overexpression models, combined with transporter biochemistry and redox measurements, provide the experimental framework for advancing this field.
References
- 1. Kong Y et al.. 2024. Ultrasmall Polyphenol-NAD(+) Nanoparticle-Mediated Renal Delivery for Mitochondrial Repair and Anti-Inflammatory Treatment of AKI-to-CKD Progression.. Adv Mater 36(30):e2310731 PMID: 38805174
- 2. Rong C et al.. 2026. SLC25A51 and mitochondrial NAD⁺ transport in acute myeloid leukemia: mechanisms, therapeutic potential, and translational perspectives.. Hum Cell 39(8) PMID: 42472419
- 3. Morré DJ et al.. 2011. Non-mitochondrial coenzyme Q.. Biofactors 37(5):355-60 PMID: 21674641
- 4. Kauppinen RA et al.. 1983. Mitochondrial membrane potential, transmembrane difference in the NAD+ redox potential and the equilibrium of the glutamate-aspartate translocase in the isolated perfused rat heart.. Biochim Biophys Acta 725(3):425-33 PMID: 6652078
- 5. Kuroda J et al.. 2010. NADPH oxidase and cardiac failure.. J Cardiovasc Transl Res 3(4):314-20 PMID: 20559780
- 6. Mercer NA et al.. 1999. Hymenolepis diminuta: catalysis of transmembrane proton translocation by mitochondrial NADPH-->NAD transhydrogenase.. Exp Parasitol 91(1):52-8 PMID: 9920042
- 7. Fu Q et al.. 2019. Purification of Adult Hymenolepis diminuta (Cestoda) Mitochondrial NADPH→NAD(+) Transhydrogenase.. J Parasitol 105(2):321-329 PMID: 30998130
- 8. Miniero DV et al.. 2024. Functional Roles of the Charged Residues of the C- and M-Gates in the Yeast Mitochondrial NAD(+) Transporter Ndt1p.. Int J Mol Sci 25(24) PMID: 39769317
